Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access advanced solid tumors specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced solid tumors treatment provided free
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible pa
Sponsor: Dragonfly Therapeutics
Check if you qualify for this advanced solid tumors clinical trial in Phoenix, AZ
If you're searching for advanced solid tumors treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.